A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia

Ponatinib may be effective in chronic myeloid leukemia (CML) patients after failure of first/second line therapies. Although its efficacy for minimum plasma concentrations (C<sub>min</sub>) is >21.3 ng/mL (equal to 40 nM), ponatinib may cause adverse events (AE) that require dose opti...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Galimberti (Author), Elisabetta Abruzzese (Author), Giacomo Luci (Author), Claudia Baratè (Author), Luigia Luciano (Author), Alessandra Iurlo (Author), Giovanni Caocci (Author), Riccardo Morganti (Author), Fabio Stefanelli (Author), Antonello Di Paolo (Author)
Format: Book
Published: MDPI AG, 2024-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available